<DOC>
	<DOCNO>NCT00109226</DOCNO>
	<brief_summary>This Phase II , multicenter , double-blind , randomize , active-controlled trial design evaluate efficacy safety rhuMAb VEGF ( Avastin ) administer dose 5 mg/kg every 2 week combination 5 FU ( fluorouracil ) /leucovorin versus 5 FU/leucovorin alone subject previously untreated metastatic colorectal cancer optimal candidate receive first-line CPT-11 ( irinotecan ) . A total 48 dos rhuMAb VEGF may administer study ( maximum 96 week therapy ) .</brief_summary>
	<brief_title>A Study Evaluate Avastin Combination With Chemotherapy Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Written inform consent Age &gt; =18 year Use effective mean contraception woman childbearing potential Histologically confirm ( resect biopsied primary tumor ) colorectal carcinoma evidence metastasis ( i.e. , radiographic image biopsy ) Ability tolerate CT contrast dye . Bidimensionally measurable disease ( minimum two lesion ) Life expectancy &gt; 3 month Willingness capability accessible followup death In addition , subject must meet least one follow criterion eligible study entry : *Age &gt; =65 year ; *ECOG performance status 1 2 ; *Albumin &lt; =3.5 g/dL ; *Prior radiotherapy abdomen pelvis ; , *in opinion treat physician , optimal candidate firstline CPT11 Prior administration chemotherapy adjuvant fluoropyrimidines combination leucovorin and/or levamisole Administration adjuvant fluoropyrimidines combination leucovorin and/or levamisole complete &lt; =12 month prior Day 0 Administration fluoropyrimidines radiosensitizer pelvic radiotherapy rectal cancer complete &lt; =12 month prior Day 0 Prior radiotherapy measurable , metastatic lesion ( ) use measure response Radiotherapy within 14 day prior Day 0 Prior administration biotherapy colorectal cancer Evidence clinically detectable ascites prior Day 0 Other invasive malignancy within 5 year Day 0 ( basal cell carcinoma skin ) History evidence upon physical examination CNS disease ( e.g. , primary brain tumor , seizures control standard medical therapy , brain metastasis ) Serious , nonhealing wound , ulcer , bone fracture Evidence bleed diathesis coagulopathy Major surgical procedure within 28 day prior Day 0 , open biopsy , significant traumatic injury , anticipation need major surgical procedure course study ; fine needle aspiration within 7 day prior Day 0 Current recent ( within 10 day prior Day 0 ) use oral parenteral anticoagulant ( except require maintain patency preexisting , permanent indwell IV catheter ) thrombolytic agent Chronic , daily treatment aspirin ( &gt; 325 mg/day ) nonsteroidal antiinflammatory medication ( kind know inhibit platelet function ) Pregnancy ( positive pregnancy test ) lactation Proteinuria baseline clinically significant impairment renal function Current recent ( within 28 day prior Day 0 ) participation another experimental drug study Active infection require parenteral antibiotic Day 0 Clinically significant cardiovascular disease ( e.g. , uncontrolled hypertension , myocardial infarction , unstable angina ) , New York Heart Association ( NYHA ) Grade II great congestive heart failure ( see Appendix H ) , serious cardiac arrhythmia require medication , Grade II great peripheral vascular disease within 1 year prior Day 0 ECOG performance status &gt; 2 Screening clinical laboratory value : *ANC &lt; =1500/uL ; *Platelet count &lt; =75,000/uL ; *International normalize ratio ( INR ) &gt; =1.5 ; *Total bilirubin &gt; 2.0 mg/dL ; *AST ALT &gt; =5 time upper limit normal subject document liver metastasis ; &gt; 2.5 time upper limit normal subject without evidence liver metastasis ; *Serum creatinine &gt; 2.0 mg/dL ; *Hemoglobin &lt; 9 gm/dL ( may transfuse maintain exceed level ) ; *Proteinuria ( 24hour urine collection demonstrate &gt; =500 mg protein/24 hr ) History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication Inability comply study visit followup schedule procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>Cancer</keyword>
</DOC>